

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 5, 2024

Brilliant Violet 650(TM) anti-mouse/human CD11b

RRID:AB_2566568

Type: Antibody

Proper Citation

(BioLegend Cat# 101259 (also 101239), RRID:AB_2566568)

Antibody Information

URL: http://antibodyregistry.org/AB_2566568

Proper Citation: (BioLegend Cat# 101259 (also 101239), RRID:AB_2566568)

Target Antigen: CD11b

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 650(TM) anti-mouse/human CD11b

Description: This monoclonal targets CD11b

Target Organism: cynomolgus, human, mouse, rhesus

Clone ID: Clone M1/70

Antibody ID: AB_2566568

Vendor: BioLegend

Catalog Number: 101259 (also 101239)

Alternative Catalog Numbers: 101239

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 650(TM) anti-mouse/human CD11b.

No alerts have been found for Brilliant Violet 650(TM) anti-mouse/human CD11b.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Liu Z, et al. (2023) Dendritic cell type 3 arises from Ly6C+ monocyte-dendritic cell progenitors. *Immunity*, 56(8), 1761.

Papaioannou S, et al. (2023) Liver sinusoidal endothelial cells orchestrate NK cell recruitment and activation in acute inflammatory liver injury. *Cell reports*, 42(8), 112836.

Ugur M, et al. (2023) Lymph node medulla regulates the spatiotemporal unfolding of resident dendritic cell networks. *Immunity*, 56(8), 1778.

Textor J, et al. (2023) Machine learning analysis of the T cell receptor repertoire identifies sequence features of self-reactivity. *Cell systems*, 14(12), 1059.

Hirschhorn D, et al. (2023) T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. *Cell*, 186(7), 1432.

Linde IL, et al. (2023) Neutrophil-activating therapy for the treatment of cancer. *Cancer cell*, 41(2), 356.

Zubeidat K, et al. (2023) Microbiota-dependent and -independent postnatal development of salivary immunity. *Cell reports*, 42(1), 111981.

Vennin C, et al. (2023) Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity. *Cancer cell*, 41(6), 1170.

Cautivo KM, et al. (2022) Interferon gamma constrains type 2 lymphocyte niche boundaries during mixed inflammation. *Immunity*, 55(2), 254.

Schönberger K, et al. (2022) Multilayer omics analysis reveals a non-classical retinoic acid signaling axis that regulates hematopoietic stem cell identity. *Cell stem cell*, 29(1), 131.

Gong Z, et al. (2022) Lipid-laden lung mesenchymal cells foster breast cancer metastasis via metabolic reprogramming of tumor cells and natural killer cells. *Cell metabolism*, 34(12),

1960.

Abdelfattah N, et al. (2022) Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. *Nature communications*, 13(1), 767.

Liu H, et al. (2022) KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer. *Cancer immunology research*, 10(8), 1028.

Uceda-Castro R, et al. (2022) Re-purposing the pro-senescence properties of doxorubicin to introduce immunotherapy in breast cancer brain metastasis. *Cell reports. Medicine*, 3(11), 100821.

Nalio Ramos R, et al. (2022) Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer. *Cell*, 185(7), 1189.

Taniguchi H, et al. (2022) WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. *Cell reports*, 39(7), 110814.

Christian DA, et al. (2022) cDC1 coordinate innate and adaptive responses in the omentum required for T cell priming and memory. *Science immunology*, 7(75), eabq7432.

Gong Z, et al. (2022) Lung fibroblasts facilitate pre-metastatic niche formation by remodeling the local immune microenvironment. *Immunity*, 55(8), 1483.

Dai X, et al. (2021) Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. *Molecular cell*, 81(11), 2317.

Rogers D, et al. (2021) Pre-existing chromatin accessibility and gene expression differences among naive CD4+ T cells influence effector potential. *Cell reports*, 37(9), 110064.